LIRYC CONTINUES TRADITION OF INNOVATION WITH FIRST COMMERCIALLY APPROVED USE OF PULSED FIELD ABLATION TECHNOLOGY TO TREAT PATIENT WITH ATRIAL FIBRILLATION

On March 23rd, 2021, Pierre Jaïs and his team performed the world’s first procedure using a CE Mark-approved PFA system on a patient with atrial fibrillation (AF).  The procedure was performed in Bordeaux, France using technology from FARAPULSE, Inc. at the Bordeaux University Hospital.

About FARAPULSE and PFA
Today, all forms of cardiac ablation to treat arrhythmias are thermal. While both radiofrequency and cryo-ablation have evolved, they nonetheless carry an inherent risk of indiscriminate thermal damage. Tissue-selective FARAPULSE PFA has emerged to be one of the most promising energy sources for cardiac ablation, including pulmonary vein isolation to treat Atrial Fibrillation. Leading with safety, FARAPULSE PFA makes durable cardiac lesions in seconds while sparing non-target tissue. As a reminder, PEF uses high-voltage electric microshocks to creates nanoscale pores in cell membranes FARAPULSE is pioneering tissue-selective PFA therapy through development and commercialization of its dedicated generator (FARASTAR), PVI-focused catheter (FARAWAVE), large-area focal catheter (FARAFLEX), precision focal catheter (FARAPOINT) and a proprietary deflectable delivery sheath (FARADRIVE). The FARAPULSE PFA system, which includes FARAWAVE, FARASTAR and FARADRIVE, received CE mark approval in January 2021 and is commercially available across Europe.